Besides, cardiac contractility modulation therapy exerted protective effects against myocardial fibrosis via inhibiting the TGF‐β1/Smad3 signalling pathway in rabbits with chronic heart failure (CHF).25 This evidence concerns the gene SMAD3 and congestive heart failure.